A part of Vision-driven Health
NextCell Pharma AB (“NextCell”) announces that it is chosen as one of the collaborators in the newly Vinnova funded project
Correction: Notice to attend the Annual General Meeting
NextCell Pharma AB (“NextCell”) announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been
Notice to attend the Annual General Meeting
NextCell Pharma AB (“NextCell”) announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been
Year-end report 2018-09-01 – 2019-08-31
Nextcell Pharma AB (“NXTCL”) today announces the year-end report for the 2018/2019 fiscal year (2018-08-31 2019-08-31) Twelve months (2018-09-01 until
NextCell invests in the Danish Cellaviva operations with a new Copenhagen office
NextCell Pharma AB (“NextCell”) today announces they are investing for growth in Cellaviva’s Danish operations with the opening of a
All patients in ProTrans-Repeat are now treated
NextCell Pharma AB (“NextCell”) announces that another significant milestone has been reached when the last patient, as part of the
Last patient, last visit completed in the dose escalation part
NextCell Pharma AB (NextCell) is today announcing that the last patient in the dose escalation part of the clinical trial
Update on the ongoing clinical trials
NextCell Pharma AB (NextCell) is today providing a status update regarding its two ongoing clinical trials, presented at the Nordic
NextCell Pharma files another patent application
NextCell Pharma AB (“NextCell”) today announces that they have filed a new patent application to the Swedish Patent and Registration
Interim report 2018-09-01 – 2019-05-31
Third quarter report By “NextCell”, “NXTCL” or “Company” is meant NextCell Pharma AB with organization number 556965-8361. “Spotlight” refers to